Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
Date:11/17/2009

CALGARY, Nov. 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers in a poster presentation at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference being held in Boston, Massachusetts. The poster presentation is entitled "Phase I/II Trial of Oncolytic Reovirus (REOLYSIN) in Combination with Carboplatin/Paclitaxel in Patients with Advanced Solid Cancers with Emphasis on Squamous Cell Carcinoma of the Head and Neck (SCCHN)."

The investigators reported that REOLYSIN was well tolerated when administered intravenously in combination with paclitaxel and carboplatin. Of 19 evaluable patients with head and neck cancer, mostly SCCHN refractory to prior platinum-based chemotherapy for recurrent/metastatic disease, eight experienced partial responses and six had stable disease. The total clinical benefit rate (complete response + partial response + stable disease) observed in head and neck cancer patients in the trial was 74%. Of four patients with malignant melanoma on the trial, one experienced a partial response and one had stable disease.

"A 42% response rate and a 74% clinical benefit rate in a platinum refractory patient population that typically has a poor prognosis and limited therapeutic options is very encouraging," said Dr. Brad Thompson, President and CEO of Oncolytics. "These results further validate our decision to advance REOLYSIN in combination with paclitaxel and carboplatin into a Phase III trial in this patient population."

An independent, confirmatory Phase II trial (REO 015) using the same combination of REOLYSIN and carboplatin/paclitaxel for patients with head and neck
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
2. Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
3. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
4. Oncolytics Biotech(R) Inc. Announces Investment in Private Biotechnology Company
5. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering Europe
6. Oncolytics Biotech(R) Inc. Accelerates Warrant Expiry Date
7. Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
8. Oncolytics Biotech(R) Inc. Announces Phase 3 Update Conference Call
9. Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial
10. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman Renshaw 11th Annual Healthcare Conference
11. Oncolytics Biotech(R) Inc. Announces Issuance of 32nd U.S. Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ... today reported financial results for the six months ... are expressed in Canadian dollars and presented under ... Quarter 2014 Highlights , Announced top-line ... (VA) primary endpoint for subjects enrolled in the ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Due to a ... last week, the Adult Stem Cell Technology Center, LLC ( ... support stem cell therapy research that might benefit ALS patients. ... cells for new stem cell technologies and therapeutic applications, FRC ... Ice Bucket Challenge donors who wish not to support ...
(Date:8/28/2014)... USA (PRWEB) August 28, 2014 SPIE ... of Physics and Optical Science and Director of the ... of North Carolina at Charlotte, and co-founder and Chairman ... to serve as the 2015 Vice President of SPIE, ... 2014 President Philip Stahl announced recent election results at ...
(Date:8/28/2014)... 28, 2014 “This kit has an improved ... from 0 to 150 ppb,” said Mark Tess, PhD, Mycotoxin ... benefit to plant owners and USDA-GIPSA inspection agencies that have ... Testing can take place in a matter of minutes with ... plant test the feed and grain before accepting it, but ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2
... CORVALLIS, Ore. Inkjet printers, a low-cost technology that in ... soon offer similar benefits for the future of solar energy. ... for the first time to create successful "CIGS" solar devices ... by 90 percent and will significantly lower the cost of ...
... HumanTouch, LLC welcomes David Meyer to our team as the ... tasked with assisting the executive leadership in building upon the ... health Information technology (IT) experience and expertise HumanTouch has been ... Senior Executive with more than 20 years of diverse experience ...
... ANGELES, June 28, 2011 Genesis Biopharma, Inc. ... therapies, is holding a conference call with the ... Noon Eastern (9:00 a.m. Pacific).  The Company,s Chairman ... provide an update on the business, and discuss ...
Cached Biology Technology:Inkjet printing could change the face of solar energy industry 2HumanTouch Welcomes David Meyer as Vice President of HumanTouch's new Health Solutions Division 2Genesis Biopharma Conference Call and Webcast Reminder 2
(Date:9/2/2014)... touch a hot oven, you rapidly pull your hand ... in sensing and responding to such painful stimuli, they ... researchers have made a surprising discovery about the role ... and have built a structural model of the molecule. ... , may help direct new strategies to treat pain ...
(Date:9/1/2014)... amount of research shows an association between TV viewing ... Now, a new Cornell University study points out that ... lead people to eat twice as much as other ... movie while snacking your mouth will see more action ... new article just published in the Journal of ...
(Date:9/1/2014)... quality of the U.S. diet showed some modest improvement ... a reduction in the consumption of unhealthy trans fats, ... the rich and the poor. , , An unhealthy ... some cancers. Eating a healthy diet is an important ... Evaluating population trends in diet quality is important because ...
Breaking Biology News(10 mins):Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3Can action movies make you fat? 2Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3
... and Washington DC (July 27, 2009) According to a ... Making , a large-scale, covert anthrax attack on a ... extremely effective public health response, primarily because of expected ... to it. The article "Predicting Hospital Surge after ...
... overall nation-wide estimate of the tiger population brought a ... by the Nepal Government,s Department of National Parks and ... 194) breeding tigers in the wild within the ... estimate was jointly implemented by the DNPWC, Department of ...
... Atrophy is the second-leading cause of infant mortality in the ... Iowa State University,s College of Veterinary Medicine, would like to ... slide off the list altogether. , Most Spinal Muscular Atrophy ... or deleted gene called Survival Motor Neuron 1 (SMN1) that ...
Cached Biology News:Bioterrorism and disaster preparedness explored in special issue of Medical Decision Making 2121 breeding tigers estimated to be found in Nepal 2ISU researchers find possible treatment for spinal muscular atrophy 2
Request Info...
Anti-ZFP200 Family: Zinc Finger Peptide Sequence: CGKSFNHKTNLNKHER...
Donor feline serum and plasma...
Collected from sexually mature, mixed sex, mixed breed cats. Physiochemical constituents are measured to ensure lot-to-lot consistency....
Biology Products: